Following an unexpected adverse clinical trial result, a pharmaceutical corporation suffers a multi-notch credit rating downgrade on its outstanding senior debentures from A to BB. During the same month, macroeconomic conditions prompt the Federal Reserve to cut interest rates, driving down benchmark market yields across all maturities. How do these concurrent developments impact an investor holding this company's corporate debentures?
- The issuer-specific credit downgrade introduces non-systematic risk that depresses the bond's price by widening its credit spread, a risk component that could have been mitigated through portfolio diversification.Answer
- BThe decline in benchmark market interest rates will automatically cause the bond's price to rise, because systemic market interest rate movements always override individual credit rating changes.
- CThe credit rating downgrade represents a systematic market risk affecting all corporate fixed-income securities in the sector equally, rendering asset diversification ineffective.
- DThe downgrade alters the tax status of the debenture's interest payments, granting federal income tax exemption to offset the heightened default exposure.
Answer
The issuer-specific credit downgrade introduces non-systematic risk that depresses the bond's price by widening its credit spread, a risk component that could have been mitigated through portfolio diversification.
A credit downgrade caused by a company-specific event (such as a failed drug trial) is a classic example of non-systematic (business or credit) risk. Although lower benchmark interest rates generally lift fixed-income prices, a multi-notch downgrade into speculative grade significantly increases the issuer's default risk premium (credit spread), causing the bond's price to decline. Because this risk is specific to the issuer, it can be minimized through portfolio diversification.
Step-by-Step Solution
Key Concept
Non-Systematic (Unsystematic) Risk and Credit Risk Mitigation
Estimated Time:1m 30s